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AN UNUSUAL CASE OF MILIARY PML-IRIS IN AN
HIV1 PATIENT
A 45-year-old female patient recently diagnosed with
HIV infection (CD41 cell count 64 cells/mm3 and
plasma HIV viral load 1.4 3 106 copies/mL at diag-
nosis) started antiretroviral therapy (ART). At the
time, she presented with gastric cryptosporidiosis
and an oral candidiasis, which subsided rapidly on
treatment. One month after ART initiation, the
patient noticed progressive generalized slowness,
speech difficulty, and a slight weakness of her right
arm and leg. She also reported headache, generalized
fatigue, night sweats, and weight loss. She was admit-
ted to the hospital 4 weeks after symptoms onset. The
neurologic examination revealed psychomotor slow-
ing, mild memory and executive dysfunction, men-
ingeal signs, dysarthria, mild lower-limb ataxia, and
right faciobrachial weakness (Medical Research
Council grade 4). Generalized adenopathy and wast-
ing syndrome were also identified. Brain MRI showed
a pattern of multiple miliary-enhancing parenchymal
nodules (1–4 mm in diameter) more marked in the
brain stem and basal ganglia (figure, A–D).
CD41 cell count was 89 cells/mm3 (11.8%), and
plasma HIV viral load had dramatically dropped at 47
copies/mL. Serological testing revealed past exposure
to Toxoplasma gondii, Epstein-Barr virus (EBV), and
cytomegalovirus (CMV). Cryptococcus neoformans
antigen and serologies for rubella virus, herpes sim-
plex viruses (HSV) 1 and 2, varicella zoster virus
(VZV), Borrelia sp, Bartonella henselae, and hepatitis
B and C were negative. Serum Treponema pallidum
hemagglutination assay and venereal disease research
laboratory test (VDRL) were nonreactive. Peripheral
blood flow cytometry showed no malignant cells.
Antinuclear antibody (anticytoplasm) titers were pos-
itive (1/640), but C3 and C4 complement titers were
within normal limits. Erythrocyte sedimentation rate
was 110, and C-reactive protein was inferior to 2
mmol/L.
CSF examination did not reveal any leukocyte or
erythrocyte; the protein content was within normal
limits (431 mg/L); and the CSF-to-serum glucose ratio
was 0.7. There was no intrathecal IgG synthesis. A
quantitative PCR for JC virus (JCV) DNAwas positive
in CSF at 965 copies/mL. All the following analyses
performed in the CSF were negative or normal: cryp-
tococcal antigen, bacterial, fungal, and acid-fast cul-
tures; PCR for Toxoplasma gondii; CMV, HSV,
VZV, and Tropheryma whipplei; VDRL; and cytology.
CSF HIV viral load was not measured. Stool specimen
analysis revealed no Entamoeba histolytica,Giardia lam-
blia, microsporidies, or Cryptosporidium.
The diagnosis of progressive multifocal encepha-
lopathy (PML) was considered. However, because
the radiologic findings were absolutely not typical
for this disease, a stereotactic brain biopsy was per-
formed. This examination showed diffuse and dense
perivascular inflammatory infiltrate (figure, E), scat-
tered atypical astrocytes with hyperchromatic nuclei
(figure, F, arrowheads), and demyelinization (figure,
G). Immunohistochemistry showed CD3 underlin-
ing dense T-lymphocyte infiltration, mostly CD81
and glial cells staining positive for JCV (figure, H–
J). The diagnosis of PML in the setting of immune
reconstitution inflammatory syndrome (IRIS) was es-
tablished, and the patient was treated with CCR5
antagonist maraviroc with a favorable outcome.
ART treatment was continued.
PML is typically associated with subcortical conflu-
ent nonenhancing lesions. However, rarely, PML may
have a “miliary” presentation.1 This form is character-
ized by enhancing punctuate lesions on brain MRI,
which correspond, histopathologically, to a perivascu-
lar inflammation composed mostly of CD81 T cells in
contact with JCV-infected glial cells.2 Such a punctate
pattern has been described in natalizumab-associated
PML,3 but may be also seen in PML classically asso-
ciated with some sort of immunosuppression, such as
neurosarcoidosis or hematologic diseases.1 A similar
radiologic pattern was also reported in a patient with
myelofibrosis exhibiting a rare mutation of the JCV
genome.4 To the best of our knowledge, only one
other case of miliary HIV-related PML has been re-
ported so far in a patient who was initially diagnosed
with EBV encephalitis.5
Our patient and the review of the literature sug-
gest that miliary PML may occur at an early stage
of JCV brain infection preceding the emergence of
typical PML lesions.1 In our case, the presence of
a strong JCV-specific cellular immune response
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suggests that miliary PML represents a very early stage
of unmasking PML-IRIS. In conclusion, this case
illustrates that a miliary or punctate pattern on brain
MRI should prompt clinicians to rule out PML.
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Figure Brain MRI
T2 axial (A) showing diffuse hyperintensities in basal ganglia and centrum semiovale on both sides, T1 transverse (B) and sagittal (C and D) showing dilated
enhancing perivascular spaces after gadolinium enhancement. Neuropathology: brain parenchyma showing diffuse and dense perivascular inflammatory
infiltrate (E, hematoxylin and eosin [H&E]), scattered atypical astrocytes with hyperchromatic nuclei (F, H&E, arrowheads), and demyelinization (G, Luxol
fast blue). CD3 (H, immunohistochemistry [IHC]) underlines dense T-lymphocyte infiltration, mostly CD81 (I, IHC). JC virus–infected oligodendrocytes (J, IHC,
arrowheads) and bizarre astrocytes (J, IHC, arrow).
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